New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 13, 2013
18:55 EDTSEAS, GT, PXD, BRCD, PMT, MM, RSH, MXC, NTI, XONE, EOG, MYGNOn The Fly: After Hours Movers
UP AFTER EARNINGS: Brocade (BRCD), up 15.9%... Myriad Genetics (MYGN), up 1.9%. ALSO HIGHER: Mexco Energy (MXC), up 26% after announcing agreements with Pioneer Natural Resources (PXD) and EOG Resources (EOG)... RadioShack (RSH), up 3.2% after Reuters reported the company is looking to refinance its debt with new, lower-cost loans... Goodyear Tire (GT), up 1.7% after Appaloosa filed an increased stake in the company. DOWN AFTER EARNINGS: ExOne (XONE), down 13%... Millennial Media (MM), down 11.6%... SeaWorld (SEAS), down 11%. ALSO LOWER: Northern Tier (NTI), down 4.5% after announcing an offering of 11.5M common units for a unitholder... PennyMac (PMT), down 3.5% after filing to sell 11.3M shares of common stock.
News For BRCD;MYGN;MXC;PXD;EOG;RSH;GT;XONE;MM;SEAS;NTI;PMT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
March 20, 2015
08:49 EDTEOGEOG Resources has a conference call hosted by JPMorgan
Subscribe for More Information
07:41 EDTMYGNAmerican Academy of Dermatology to hold annual meeting
Subscribe for More Information
05:17 EDTMYGNMyriad EMPATHY-P clinical study results to be highlighted at annual congress
Myriad Genetics announced that results from the EMPATHY-P clinical study of Prolaris in patients newly diagnosed with prostate cancer will be highlighted at the 30th Annual Congress of the European Association of Urology. The EMPATHY-P study evaluated the Prolaris test on 525 patient biopsy samples to determine the aggressiveness of prostate cancer in these newly diagnosed patients from five European countries including: Italy, Germany, Spain, Switzerland and the UK. The patients' biopsy samples also were evaluated using standard clinical pathology methods, which were then compared to the Prolaris test results. The EMPATHY-P data showed, overall, that the Prolaris test found 42% of the European men evaluated had a risk profile that was either lower or higher than would be expected using clinical pathology. Interestingly, this finding is consistent with the previously published U.S. Prostate Biopsy Research study, which found 51% of U.S. patients had a risk profile that differed from clinical pathology.
March 19, 2015
18:58 EDTSEASOn The Fly: After Hours Movers
UP AFTER EARNINGS: Mattress Firm (MFRM), up 5.2%... New York & Company (NWY), up 3.1%... Rally Software (RALY), up 1.4%... Nike (NKE), up 4.2%... Youku Tudou (YOKU), up 1%. ALSO HIGHER: Prothena (PRTA), up 39.3% after reporting positive results from Phase 1 study of PRX002... SeaWorld (SEAS), up 1% after naming Joel Manby as president and CEO. DOWN AFTER EARNINGS: AK Steel (AKS), down 9.1%.
16:02 EDTSEASSeaWorld names Joel Manby as President And CEO
SeaWorld Entertainment announced that its board has appointed Joel Manby as President and CEO, effective April 7. Manby will also join the company's board. David D'Alessandro, who has served as interim CEO, will continue to serve as the company's Chairman. Most recently, Manby has served as President and Chief Executive Officer of Herschend Enterprises, the largest family-owned theme park and entertainment company in the U.S.
March 18, 2015
13:13 EDTEOGAnalyst recommends buying top E&P names before crude finds its bottom
Subscribe for More Information
09:31 EDTPXDPioneer Natural downgraded to Equalweight from Overweight at Capital One
Capital One downgraded Pioneer Natural to reflect lower oil, gas, and NGL price deck forecasts and said valuation is lofty. Price target is $163.
07:21 EDTEOGE&P stocks should be bought on weakness, says Stifel
Subscribe for More Information
March 17, 2015
10:00 EDTXONEOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:25 EDTXONEOn The Fly: Pre-market Movers
Subscribe for More Information
07:40 EDTXONEExOne guidance 'pretty good,' says Oppenheimer
Subscribe for More Information
07:18 EDTMYGNMyriad Genetics announces collaboration expansion with BioMarin
Myriad Genetics (MYGN) announced an expansion of the company's collaboration with BioMarin Pharmaceutical (BMRN). Under the expanded collaboration, BioMarin will use Myriad's myChoice HRD companion diagnostic test to prospectively identify patients with metastatic breast, ovarian and potentially other tumor types that may be sensitive to talazoparib. Financial terms were not disclosed.
05:39 EDTXONEExOne downgraded to Market Perform from Outperform at FBR Capital
Subscribe for More Information
March 16, 2015
19:00 EDTXONEOn The Fly: After Hours Movers
Subscribe for More Information
17:18 EDTXONEExOne sees FY15 revenue $58M-$66M, consensus $61.77M
Subscribe for More Information
17:17 EDTXONEExOne reports Q4 EPS (50c), may not compare to consensus (5c)
Subscribe for More Information
15:06 EDTEOGEOG Resources calls active
Subscribe for More Information
09:36 EDTEOGEOG Resources could be a target for Statoil, Houston Business Journal says
Subscribe for More Information
07:53 EDTXONEExOne March volatility elevated at 135 into Q4 and outlook
Subscribe for More Information
07:26 EDTPMTPennyMac Mortgage remains a top pick following weakness at Credit Suisse
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use